Levofloxacin Hemihydrate API

Mechanism of Action

Levofloxacin inhibits bacterial type II topoisomerases, topoisomerase IV and DNA gyrase. Levofloxacin, like other fluoroquinolones, inhibits the A subunits of DNA gyrase, two subunits encoded by the gyrA gene. This results in strand breakage on a bacterial chromosome, supercoiling, and resealing; DNA replication and transcription is inhibited.

Indication

LEVAQUIN® is a fluoroquinolone antibacterial indicated in adults (18 years of age and older) with infections caused by designated, susceptible bacteria and in pediatric patients where indicated. 

• Pneumonia: Nosocomial and Community Acquired
• Skin and Skin Structure Infections (SSSI): Complicated and Uncomplicated
• Chronic bacterial prostatitis
• Inhalational Anthrax, Post-Exposure in adult and pediatric patients
• Plague in adult and pediatric patients
• Urinary Tract Infections (UTI): Complicated and Uncomplicated
• Acute Pyelonephritis
• Acute Bacterial Exacerbation of Chronic Bronchitis
• Acute Bacterial Sinusitis

Usage:

To reduce the development of drug-resistant bacteria and maintain the effectiveness of LEVAQUIN® and other antibacterial drugs, LEVAQUIN® should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria IQUIX® solution is a topical quinolone antimicrobial indicated for the treatment of corneal ulcer caused by susceptible strains of the following bacteria: 

• Corynebacterium species*
• Staphylococcus aureus
• Staphylococcus epidermidis
• Streptococcus pneumonia
• Viridans group streptococci*
• Pseudomonas aeruginosa
• Serratia marcescens*